Start Date
August 31, 2020
Primary Completion Date
August 31, 2020
Study Completion Date
August 31, 2020
Atezolizumab
Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
Health Pharma Professional Research, Mexico City
Lead Sponsor
Health Pharma Professional Research
OTHER